You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR AZASAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for AZASAN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00774852 ↗ Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Completed Immune Tolerance Network (ITN) Phase 2 2008-11-01 This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
NCT00774852 ↗ Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2008-11-01 This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AZASAN

Condition Name

Condition Name for AZASAN
Intervention Trials
Lupus Erythematosus, Systemic 1
Lupus Nephritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AZASAN
Intervention Trials
Lupus Erythematosus, Systemic 1
Nephritis 1
Lupus Nephritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AZASAN

Trials by Country

Trials by Country for AZASAN
Location Trials
United States 13
Mexico 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for AZASAN
Location Trials
Texas 1
South Carolina 1
Pennsylvania 1
Oklahoma 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AZASAN

Clinical Trial Phase

Clinical Trial Phase for AZASAN
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AZASAN
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AZASAN

Sponsor Name

Sponsor Name for AZASAN
Sponsor Trials
Immune Tolerance Network (ITN) 1
National Institute of Allergy and Infectious Diseases (NIAID) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AZASAN
Sponsor Trials
Other 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.